Publicou 4 edições por ano
ISSN Imprimir: 0731-8898
ISSN On-line: 2162-6537
Indexed in
MET and Phosphorylated MET as Potential Biomarkers in Lung Cancer
RESUMO
This study aimed to investigate the expression and prognostic role of the receptor tyrosine kinase MET, phosphorylated MET, and the ligand hepatocyte growth factor (HGF) in patients with lung cancer. This retrospective study included 129 patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) with available tumor tissue and survival data. MET, pMET, and HGF expression were assessed using immunohistochemistry. MET, pMET, and HGF were more highly expressed in tumor tissue when compared to the adjacent lung parenchyma. A specific localization pattern was also evident: membranous, cytoplasmic, and nuclear patterns of expression were seen for MET, pMET, and HGF. In addition, high expression of two specific forms of phosphorylated MET−cytoplasmic expression of Y1003 and nuclear expression of Y1365−appeared to correlate with a worse overall survival (P = .016; hazard ratio [HR], 1.86; 95% confidence interval [95% CI], 1.12— 3.07; and P = .034; HR, 1.70; 95% CI, 1.04—2.78, respectively). In summary, MET, pMET, and HGF are highly expressed in both NSCLC and SCLC. Specific forms of pMET may serve as potential biomarkers in lung cancer.
-
Chakravarty Swapnajit, Lai Wei-Cheng, Zou Yi, Drabkin Harry A., Gemmill Robert M., Simon George R., Chin Steve H., Chen Ray T., Multiplexed specific label-free detection of NCI-H358 lung cancer cell line lysates with silicon based photonic crystal microcavity biosensors, Biosensors and Bioelectronics, 43, 2013. Crossref
-
Maroun Christiane R., Rowlands Tracey, The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance, Pharmacology & Therapeutics, 142, 3, 2014. Crossref
-
Li Anna, Gao Hong-Fei, Wu Yi-Long, Targeting the MET pathway for potential treatment of NSCLC, Expert Opinion on Therapeutic Targets, 19, 5, 2015. Crossref
-
Samei Lv, Yaling Pang, Lihua Yang, Yan Zhang, Shuyan Jiang, Effects and Mechanism of Imatinib in Inhibiting Colon Cancer Cell Proliferation, Medical Science Monitor, 22, 2016. Crossref
-
Qiu Tian, Li Weihua, Zhang Tongtong, Xing Puyuan, Huang Wenting, Wang Bingning, Chu Lixia, Guo Lei, Liu Xiuyun, Li Yan, Ying Jianming, Li Junling, Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Non–small-cell Lung Cancer, Clinical Lung Cancer, 19, 4, 2018. Crossref
-
Wu Yi-Long, Soo Ross Andrew, Locatelli Giuseppe, Stammberger Uz, Scagliotti Giorgio, Park Keunchil, Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?, Cancer Treatment Reviews, 61, 2017. Crossref
-
Pei Jun, Chu Tianqing, Shao Minhua, Teng Jiajun, Sha Huifang, Gu Aiqing, Li Rong, Qian Jialin, Mao Weifeng, Li Ying, Han Baohui, Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells, Yonsei Medical Journal, 58, 3, 2017. Crossref
-
Orlando Eleonora, Aebersold Daniel Matthias, Medová Michaela, Zimmer Yitzhak, Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase, Cancer Letters, 443, 2019. Crossref
-
Miao Yun L., Xu Qing Qing, MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma, Lung Cancer, 130, 2019. Crossref
-
Xiao Juanjuan, Wang Fei, Lu Hui, Xu Sanpeng, Zou Ling, Tian Qin, Fu Yang, Lin Xuan, Liu Lin, Yuan Ping, Ni Xiaofang, Ma Tengfei, Zeng Fanfan, Xue Peipei, Xiu Ruijuan, Zhang Jianmin, Ji Xinying, Hu Hongbo, Lu Shangyun, Dai Hongtian, Li Yuan, Chu Qian, Zhao Xia, Duan Qiuhong, Zhu Feng, Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells, Cell Death & Disease, 10, 10, 2019. Crossref
-
Du Yi, Hsu Jennifer L., Wang Ying-Nai, Hung Mien-Chie, Nuclear Functions of Receptor Tyrosine Kinases, in Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease, 2015. Crossref
-
Koch Jonas P., Aebersold Daniel M., Zimmer Yitzhak, Medová Michaela, MET targeting: time for a rematch, Oncogene, 39, 14, 2020. Crossref
-
Liang Hongge, Wang Mengzhao, <p>MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis</p>, OncoTargets and Therapy, Volume 13, 2020. Crossref
-
Chiappetta Gennaro, Basile Anna, Barbieri Antonio, Falco Antonia, Rosati Alessandra, Festa Michelina, Pasquinelli Rosa, Califano Daniela, Palma Giuseppe, Costanzo Raffaele, Barcaroli Daniela, Capunzo Mario, Franco Renato, Rocco Gaetano, Pascale Maria, Turco Maria Caterina, De Laurenzi Vincenzo, Arra Claudio, The anti-apoptotic BAG3 protein is expressed in lung carcinomas and regulates small cell lung carcinoma (SCLC) tumor growth, Oncotarget, 5, 16, 2014. Crossref
-
Kawada Ichiro, Hasina Rifat, Arif Qudsia, Mueller Jeffrey, Smithberger Erin, Husain Aliya N., Vokes Everett E., Salgia Ravi, Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non–Small Cell Lung Cancer, Cancer Research, 74, 3, 2014. Crossref
-
Penuel Elicia, Li Congfen, Parab Vaishali, Burton Luciana, Cowan Kyra J., Merchant Mark, Yauch Robert L., Patel Premal, Peterson Amy, Hampton Garret M., Lackner Mark R., Hegde Priti S., HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors, Molecular Cancer Therapeutics, 12, 6, 2013. Crossref
-
Salgia Ravi, MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale, Molecular Cancer Therapeutics, 16, 4, 2017. Crossref